We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

Mepolizumab is additionally indicated for treating CRSwNP. Depemokimab, a novel treatment, differs from mepolizumab due to specific modifications in its amino acid sequence. These alterations enhance ...

GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. A commercial launch for ...

GSK plc GSK announced that the FDA has approved ... Other planned launches include Blenrep (for multiple myeloma), depemokimab (chronic rhinosinusitis with nasal polyps and asthma with type ...

GSK is opening the door to a new era in urinary ... plus a new launch for biologic depemokimab. All five should help the company achieve its recently increased 2031 sales goal of more than 40 ...

In 2025, GSK expects to launch five new products/line extensions, including Blenrep, depemokimab (severe asthma and CRSwNP), Nucala for COPD, gepotidacin and pentavalent MenABCWY meningococcal ...

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The ...

These include Blenrep for multiple myeloma and depemokimab for severe asthma. Overall, GSK ranks 6th on our list of the most undervalued biotech stocks to invest in. While we acknowledge the ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other most undervalued ...

Europe has had the highest number of measles cases since 1997, according to a new report from the World Health Organization (WHO). There were 127,350 cases in 2024 – about double the number from ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former GSK leaders to its board. The biotech’s series B was led by new ...